Cargando…

Study on Management of Blood Transfusion Therapy in Patients with Hereditary Spherocytosis

Hereditary spherocytosis (HS) is a chronic hemolytic disorder caused by inherited defects in the red blood cell membrane. This study discusses the treatment strategy for the decline in hemoglobin level in three HS probands with moderately severe or severe hemolysis and summarizes the appropriate lab...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Shiyue, Tang, Lingjian, Wu, Chaoli, Tang, Hui, Pu, Xue, Niu, Jinhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8816590/
https://www.ncbi.nlm.nih.gov/pubmed/35126660
http://dx.doi.org/10.1155/2022/6228965
_version_ 1784645470023319552
author Ma, Shiyue
Tang, Lingjian
Wu, Chaoli
Tang, Hui
Pu, Xue
Niu, Jinhong
author_facet Ma, Shiyue
Tang, Lingjian
Wu, Chaoli
Tang, Hui
Pu, Xue
Niu, Jinhong
author_sort Ma, Shiyue
collection PubMed
description Hereditary spherocytosis (HS) is a chronic hemolytic disorder caused by inherited defects in the red blood cell membrane. This study discusses the treatment strategy for the decline in hemoglobin level in three HS probands with moderately severe or severe hemolysis and summarizes the appropriate laboratory tests that help improve clinical management of blood transfusion in HS patients. Three probands who were diagnosed with HS in our hospital and their family members were included in this study. Clinical data of the three families were reviewed to summarize their hematopoietic characteristics. DNA from all family members of the 3 HS probands was amplified by polymerase chain reaction (PCR) and sequenced by the Sanger method to assess genetic relation for HS. Based on the sequencing results, the type of mutated membrane protein in each proband was analyzed using the eosin-5′-maleimide (EMA) binding test and sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The hemoglobin level was reduced in all 3 probands after different levels of infection. The fluorescence of EMA-labeled red blood cell (RBC) was decreased. DNA sequencing showed that His54Pro, Leu1858Val, and 6531-12C>T compound heterozygous mutations were present in the SPTA1 gene of patient I-1, Arg344Gln and c.609+86G>A heterozygous mutations were present in the SLC4A1 gene of patient II-1, and Leu2032Pro homozygous mutation was present in the SPTB gene of patient III-1. SDS-PAGE results demonstrated that the concentration of band 3 was reduced in II-1, whereas the levels of the corresponding mutant proteins in the other probands were unchanged. The family members of the respective patients presented mutations in major genes causing HS. The Leu2032Pro mutation identified in patient III-1 is a new missense mutation of the SPTB gene in the Chinese population that has never been reported in literature previously. The presence or absence of acute or chronic infections is a critical deciding factor for the treatment and clinical management of HS patient via blood transfusion. For patients with infections, hemoglobin concentration can be restored once the infection is controlled, thus obviating the need for proper infection control before blood transfusion.
format Online
Article
Text
id pubmed-8816590
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-88165902022-02-05 Study on Management of Blood Transfusion Therapy in Patients with Hereditary Spherocytosis Ma, Shiyue Tang, Lingjian Wu, Chaoli Tang, Hui Pu, Xue Niu, Jinhong Appl Bionics Biomech Research Article Hereditary spherocytosis (HS) is a chronic hemolytic disorder caused by inherited defects in the red blood cell membrane. This study discusses the treatment strategy for the decline in hemoglobin level in three HS probands with moderately severe or severe hemolysis and summarizes the appropriate laboratory tests that help improve clinical management of blood transfusion in HS patients. Three probands who were diagnosed with HS in our hospital and their family members were included in this study. Clinical data of the three families were reviewed to summarize their hematopoietic characteristics. DNA from all family members of the 3 HS probands was amplified by polymerase chain reaction (PCR) and sequenced by the Sanger method to assess genetic relation for HS. Based on the sequencing results, the type of mutated membrane protein in each proband was analyzed using the eosin-5′-maleimide (EMA) binding test and sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The hemoglobin level was reduced in all 3 probands after different levels of infection. The fluorescence of EMA-labeled red blood cell (RBC) was decreased. DNA sequencing showed that His54Pro, Leu1858Val, and 6531-12C>T compound heterozygous mutations were present in the SPTA1 gene of patient I-1, Arg344Gln and c.609+86G>A heterozygous mutations were present in the SLC4A1 gene of patient II-1, and Leu2032Pro homozygous mutation was present in the SPTB gene of patient III-1. SDS-PAGE results demonstrated that the concentration of band 3 was reduced in II-1, whereas the levels of the corresponding mutant proteins in the other probands were unchanged. The family members of the respective patients presented mutations in major genes causing HS. The Leu2032Pro mutation identified in patient III-1 is a new missense mutation of the SPTB gene in the Chinese population that has never been reported in literature previously. The presence or absence of acute or chronic infections is a critical deciding factor for the treatment and clinical management of HS patient via blood transfusion. For patients with infections, hemoglobin concentration can be restored once the infection is controlled, thus obviating the need for proper infection control before blood transfusion. Hindawi 2022-01-28 /pmc/articles/PMC8816590/ /pubmed/35126660 http://dx.doi.org/10.1155/2022/6228965 Text en Copyright © 2022 Shiyue Ma et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Ma, Shiyue
Tang, Lingjian
Wu, Chaoli
Tang, Hui
Pu, Xue
Niu, Jinhong
Study on Management of Blood Transfusion Therapy in Patients with Hereditary Spherocytosis
title Study on Management of Blood Transfusion Therapy in Patients with Hereditary Spherocytosis
title_full Study on Management of Blood Transfusion Therapy in Patients with Hereditary Spherocytosis
title_fullStr Study on Management of Blood Transfusion Therapy in Patients with Hereditary Spherocytosis
title_full_unstemmed Study on Management of Blood Transfusion Therapy in Patients with Hereditary Spherocytosis
title_short Study on Management of Blood Transfusion Therapy in Patients with Hereditary Spherocytosis
title_sort study on management of blood transfusion therapy in patients with hereditary spherocytosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8816590/
https://www.ncbi.nlm.nih.gov/pubmed/35126660
http://dx.doi.org/10.1155/2022/6228965
work_keys_str_mv AT mashiyue studyonmanagementofbloodtransfusiontherapyinpatientswithhereditaryspherocytosis
AT tanglingjian studyonmanagementofbloodtransfusiontherapyinpatientswithhereditaryspherocytosis
AT wuchaoli studyonmanagementofbloodtransfusiontherapyinpatientswithhereditaryspherocytosis
AT tanghui studyonmanagementofbloodtransfusiontherapyinpatientswithhereditaryspherocytosis
AT puxue studyonmanagementofbloodtransfusiontherapyinpatientswithhereditaryspherocytosis
AT niujinhong studyonmanagementofbloodtransfusiontherapyinpatientswithhereditaryspherocytosis